{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:11:24Z","timestamp":1778231484271,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Erythrodermic psoriasis (EP) is a rare but severe inflammatory skin disease that affects the whole body. It presents clinically as widespread redness, scaling, and systemic symptoms. Treatment choices are currently limited, and conventional drugs often raise safety issues, highlighting the need for more effective and safer treatments. Biologics have emerged as a new approach. This study aimed to systematically evaluate the efficacy and safety of different biologics for EP by conducting a systematic review and single-arm meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic search of four databases\u2014Embase, PubMed, Scopus, and the Cochrane Library\u2014for relevant clinical studies published up to May 2025. Treatment effects were evaluated by analyzing statistical data such as single-arm PASI 75 response rates and their 95% confidence intervals (CI). Heterogeneity was assessed using the I\u00b2 statistic, and subgroup analyses were conducted based on drug targets and treatment duration. A random-effects meta-analysis was applied to quantitatively synthesize the data. All statistical analyses were performed using Stata 18.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18 studies involving 342 patients were included in the analysis. Patients receiving IL-17-targeted biologics achieved higher PASI 75 response rates compared to those treated with TNF-\u03b1 or IL-23-targeted biologics. Response rates for IL-17-targeted agents continued to climb over 12 weeks, peaking at 82% by week 16, indicating superior efficacy in improving skin lesions compared to other biologic categories. IL-23-targeted biologics exhibited the lowest incidence of adverse events (5%, 95% confidence interval: 4%-13%), suggesting superior safety compared to IL-17 and TNF-\u03b1-targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This single-arm meta-analysis demonstrates the efficacy and safety of biologics in treating erythrodermic psoriasis (EP). These treatments are particularly valuable for rapid control and long-term management of the disease. Further large-scale studies with long-term follow-up are needed to confirm their benefits in specific patient groups and for preventing recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1714587","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:29:25Z","timestamp":1761715765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of biologics in erythrodermic psoriasis: a systematic review and single-arm meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Lingjie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]},{"name":"School of Nursing, China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]},{"name":"School of Nursing, China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Shengjing Hospital Affiliated to China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[{"name":"Shengjing Hospital Affiliated to China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Nursing Department, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1977.tb00303.x","article-title":"Free radical theory of aging: effect of age, sex and dietary precursors on rat-brain docosahexanoic acid","volume":"25","author":"Eddy","year":"1977","journal-title":"J Am Geriatr Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2011.8","article-title":"The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury","volume":"8","author":"Yamada","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PTT.S288345","article-title":"Updates on the treatment of erythrodermic psoriasis","volume":"11","author":"Lo","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0116","article-title":"Psoriatic erythroderma caused by terbinafine: A possible pathogenetic role for IL-23","volume":"27","author":"Oda","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13883","article-title":"Evaluation of ICAM-1 expression and vascular changes in the skin of patients with plaque, pustular, and erythrodermic psoriasis","volume":"57","author":"Bressan","year":"2018","journal-title":"Int J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7531","article-title":"Diagnosis and management of pediatric psoriasis: an overview for pediatricians","volume":"22","author":"Hebert","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1000776","article-title":"The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain","volume":"11","author":"Maravilla-Herrera","year":"2023","journal-title":"Front Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.mjafi.2021.07.009","article-title":"Use of secukinumab in erythrodermic psoriasis: A single center experience","volume":"79","author":"Bhatnagar","year":"2023","journal-title":"Med J Armed Forces India"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00480-x","article-title":"Treatment response of patients with erythrodermic psoriasis after switching to guselkumab","volume":"11","author":"Chiang","year":"2021","journal-title":"Dermatol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/jcm8060770","article-title":"Use of secukinumab in a cohort of erythrodermic psoriatic patients: A pilot study","volume":"8","author":"Damiani","year":"2019","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07217.x","article-title":"Treatment of erythrodermic psoriasis with etanercept","volume":"155","author":"Esposito","year":"2006","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70080","article-title":"Clinical experience of risankizumab in patients with a history of erythrodermic psoriasis","volume":"34","author":"Hsu","year":"2025","journal-title":"Exp Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_51_20","article-title":"Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study","volume":"39","author":"Lo","year":"2021","journal-title":"Dermatol Sin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00666-x","article-title":"Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis","volume":"12","author":"Morita","year":"2022","journal-title":"Dermatol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00741-x","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results","volume":"12","author":"Okubo","year":"2022","journal-title":"Dermatol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_221_21","article-title":"Secukinumab in erythrodermic psoriasis: Real world experience of 6 patients successfully treated by injecting at unconventional sites","volume":"66","author":"Panda","year":"2021","journal-title":"Indian J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.325","article-title":"Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice","volume":"3","author":"Plana","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19371","article-title":"Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice","volume":"37","author":"Reymundo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10940.x","article-title":"Efficacy and safety of biologics in erythrodermic psoriasis: A multicentre, retrospective study","volume":"167","author":"Viguier","year":"2012","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/ijd.ijd_1051_23","article-title":"Efficacy and safety of adalimumab and secukinumab in erythrodermic psoriasis: A single centre retrospective study","volume":"70","author":"Wang","year":"2025","journal-title":"Indian J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16252","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20210644","article-title":"Clinical efficacy and safety of secukinumab in the treatment of seven cases of erythrodermic psoriasis","volume":"55","author":"Zhang","year":"2022","journal-title":"Chin J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1473356","article-title":"Effectiveness, quality of life, and safety of secukinumab versus conventional systemic therapy in patients with erythrodermic psoriasis: a comparative study","volume":"11","author":"Zhou","year":"2024","journal-title":"Front Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.06202-8","article-title":"Psoriasis and the TNF\/IL23\/IL17 axis","volume":"154","author":"Furue","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7692024","article-title":"T helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.014","article-title":"From empirical to pathogenesis-based treatments for psoriasis","volume":"142","author":"van de Kerkhof","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2011.1452","article-title":"Psoriatic arthritis: from a dermatological perspective","volume":"21","author":"Yamamoto","year":"2011","journal-title":"Eur J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.008","article-title":"IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis","volume":"136","author":"Xing","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.36948\/ijfmr.2024.v06i06.29806","article-title":"Comparative efficacy and safety of TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors in the treatment of moderate to severe psoriasis: A systematic review","volume":"6","author":"Parthasarathi","year":"2024","journal-title":"Int J For Multidiscip Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn114015-20220510-00410","article-title":"Research progress on adverse reactions associated with biologic therapies for psoriasis","volume":"25","author":"Huiping","year":"2023","journal-title":"J Adverse Drug Reactions"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.13735\/j.cjdv.1001-7089.202409034","article-title":"Expert consensus on chronic disease management of psoriasis","volume":"39","author":"Xuejun","year":"2025","journal-title":"J Chinese Dermatol Venereol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1848885","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:38:13Z","timestamp":1778229493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1714587"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1714587","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1714587"}}